GS
LABD icon

GTS Securities’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

GTS Securities’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,240
Closed -$72.4K – 2789
2024
Q3 		$72.4K Sell
1,240
-2,590
-68% -$157K ﹤0.01% 3849
2024
Q2 		$281K Buy
3,830
+180
+5% +$15.2K ﹤0.01% 3184
2024
Q1 		$266K Buy
3,650
+980
+37% +$81.8K ﹤0.01% 3100
2023
Q4 		$259K Sell
2,670
-350
-12% -$68.1K ﹤0.01% 3342
2023
Q3 		$622K Buy
+3,020
New +$491K ﹤0.01% 2405

Other funds holding LABD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Capstone Capital Management Hong Kong $224M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

GTS Securities's LABD Position: Q1 2026 in Review

GTS Securities reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 0.36% in Q1 2026, selling an estimated $2.88K and leaving 42,361 shares worth $690K. The position accounts for 0.02% of the portfolio, ranked #553.

GTS Securities first reported a position in LABD in Q2 2023 and has held it in 10 quarters since. The position peaked at $966K in Q3 2023. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • GTS Securities held 42,361 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $690K as of Q1 2026.
  • GTS Securities sold 152 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $2.88K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up 0.02% of GTS Securities's portfolio in Q1 2026, its #553 holding.
  • GTS Securities first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2023 and has held it in 10 quarters since.
  • GTS Securities's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $966K in Q3 2023.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.